In a cohort of 300 CLL patients, Bologna et al. (2016) observed that the expression of SLAMF1/CD150 (as analyzed by flow cytometry) was lost in a subset of patients with an aggressive CLL that was associated with a shorter time to first treatment and reduced overall survival. This evidence concerns the gene SLAMF1 and B-cell chronic lymphocytic leukemia.